Cognitive-Behavioral Therapy for Children With Nightmares
Launched by UNIVERSITY OF OKLAHOMA · Sep 5, 2023
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a type of therapy called Cognitive-Behavioral Therapy for Nightmares in children aged 6 to 17. The main goal is to see if this therapy can help reduce the number and distress of nightmares in kids who have them frequently. Researchers want to find out if reducing nightmares also helps improve overall mental health and reduces feelings of sadness or thoughts about hurting oneself.
To participate, children need to be between 6 and 17 years old and must experience recurring nightmares that fit specific criteria. They should understand and speak English at least at a 6-year-old level. It's important that a parent or guardian attends the study visits with them. Children on certain medications must be stable for at least 30 days before joining. Participants will need access to Wi-Fi and a device with a camera for online sessions. If a child is found to be in immediate danger or at risk of self-harm, their family will be referred for urgent care, and they won't be able to participate in the study until they are safe. This study is currently recruiting participants, so if you think it might be a good fit, reach out for more information!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Child must be between ages of 6-17 years 11 months.
- • Child must report recurrent nightmares that meet Diagnostic and Statistical Manual of Mental Disorders criteria for nightmare disorder.
- • Child must speak and understand English at no less than a 6-year-old level.
- • Children on prescribed psychotropic medications must be stable for 30 days prior to enrolling.
- • Child must have a parent or legal guardian attend study visits with them.
- • Participants must have access to WIFI/phone data in order to participate in this study and must have an electronic device with a camera enabled.
- Exclusion Criteria:
- • Children with a diagnosis of sleep apnea which is not adequately treated.
- • Children whose receptive/expressive language skills are below a 6-year-old level.
- • If it is determined that a child is actively suicidal and at imminent risk for self-harm, the family will be notified and referred for immediate care. They will not be eligible for the study until they are deemed stable.
About University Of Oklahoma
The University of Oklahoma, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials and research initiatives. With a robust network of interdisciplinary experts and state-of-the-art facilities, the university fosters an environment that promotes scientific discovery and the development of new treatments. Its commitment to patient-centered research ensures that clinical trials not only adhere to the highest ethical standards but also aim to address pressing health challenges. By collaborating with various stakeholders, including industry partners and healthcare providers, the University of Oklahoma seeks to translate research findings into tangible benefits for communities, ultimately enhancing the quality of care and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tulsa, Oklahoma, United States
Tulsa, Oklahoma, United States
Patients applied
Trial Officials
Lisa Cromer, PhD
Principal Investigator
University of Tulsa
Tara Buck, MD
Principal Investigator
University of Oklahoma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported